Literature DB >> 24247135

Towards a paradigm shift in the treatment of chronic Chagas disease.

R Viotti1, B Alarcón de Noya, T Araujo-Jorge, M J Grijalva, F Guhl, M C López, J M Ramsey, I Ribeiro, A G Schijman, S Sosa-Estani, F Torrico, J Gascon.   

Abstract

Treatment for Chagas disease with currently available medications is recommended universally only for acute cases (all ages) and for children up to 14 years old. The World Health Organization, however, also recommends specific antiparasite treatment for all chronic-phase Trypanosoma cruzi-infected individuals, even though in current medical practice this remains controversial, and most physicians only prescribe palliative treatment for adult Chagas patients with dilated cardiomyopathy. The present opinion, prepared by members of the NHEPACHA network (Nuevas Herramientas para el Diagnóstico y la Evaluación del Paciente con Enfermedad de Chagas/New Tools for the Diagnosis and Evaluation of Chagas Disease Patients), reviews the paradigm shift based on clinical and immunological evidence and argues in favor of antiparasitic treatment for all chronic patients. We review the tools needed to monitor therapeutic efficacy and the potential criteria for evaluation of treatment efficacy beyond parasitological cure. Etiological treatment should now be mandatory for all adult chronic Chagas disease patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24247135      PMCID: PMC3910900          DOI: 10.1128/AAC.01662-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  48 in total

Review 1.  Chagas' disease and the autoimmunity hypothesis.

Authors:  F Kierszenbaum
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

Review 2.  Where do we stand on the autoimmunity hypothesis of Chagas disease?

Authors:  Felipe Kierszenbaum
Journal:  Trends Parasitol       Date:  2005-08-25

3.  Parasite persistence correlates with disease severity and localization in chronic Chagas' disease.

Authors:  L Zhang; R L Tarleton
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

4.  Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.

Authors:  Simone Garcia; Carolina O Ramos; Juliana F V Senra; Fabio Vilas-Boas; Maurício M Rodrigues; Antonio C Campos-de-Carvalho; Ricardo Ribeiro-Dos-Santos; Milena B P Soares
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

Review 5.  Chronic chagasic cardiopathy: the product of a turbulent host-parasite relationship.

Authors:  M de L Higuchi
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1997 Jan-Feb       Impact factor: 1.846

6.  Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection.

Authors:  A L de Andrade; F Zicker; R M de Oliveira; S Almeida Silva; A Luquetti; L R Travassos; I C Almeida; S S de Andrade; J G de Andrade; C M Martelli
Journal:  Lancet       Date:  1996-11-23       Impact factor: 79.321

7.  Reversibility of cardiac fibrosis in mice chronically infected with Trypanosoma cruzi, under specific chemotherapy.

Authors:  S G Andrade; S Stocker-Guerret; A S Pimentel; J A Grimaud
Journal:  Mem Inst Oswaldo Cruz       Date:  1991 Apr-Jun       Impact factor: 2.743

8.  Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease.

Authors:  S Sosa Estani; E L Segura; A M Ruiz; E Velazquez; B M Porcel; C Yampotis
Journal:  Am J Trop Med Hyg       Date:  1998-10       Impact factor: 2.345

9.  Clinical characteristics and outcome of 107 adult patients with chronic Chagas disease and parasitological cure criteria.

Authors:  Graciela L Bertocchi; Carlos A Vigliano; Bruno G Lococo; Marcos A Petti; Rodolfo J Viotti
Journal:  Trans R Soc Trop Med Hyg       Date:  2013-04-23       Impact factor: 2.184

10.  Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up.

Authors:  R Viotti; C Vigliano; H Armenti; E Segura
Journal:  Am Heart J       Date:  1994-01       Impact factor: 4.749

View more
  76 in total

1.  Drug Susceptibility of Genetically Engineered Trypanosoma cruzi Strains and Sterile Cure in Animal Models as a Criterion for Potential Clinical Efficacy of Anti-T. cruzi Drugs.

Authors:  Julio A Urbina; James H McKerrow
Journal:  Antimicrob Agents Chemother       Date:  2015-12       Impact factor: 5.191

2.  Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?

Authors:  Irene Losada Galván; Olaya Madrid Pascual; Juan María Herrero-Martínez; Ana Pérez-Ayala; Manuel Lizasoain Hernández
Journal:  Am J Trop Med Hyg       Date:  2019-06       Impact factor: 2.345

3.  Lychnopholide in Poly(d,l-Lactide)-Block-Polyethylene Glycol Nanocapsules Cures Infection with a Drug-Resistant Trypanosoma cruzi Strain at Acute and Chronic Phases.

Authors:  Renata Tupinambá Branquinho; Carlos Geraldo Campos de Mello; Maykon Tavares Oliveira; Levi Eduardo Soares Reis; Paula Mello de Abreu Vieira; Dênia Antunes Saúde-Guimarães; Vanessa Carla Furtado Mosqueira; Marta de Lana
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

4.  Population pharmacokinetics of benznidazole in adult patients with Chagas disease.

Authors:  D Soy; E Aldasoro; L Guerrero; E Posada; N Serret; T Mejía; J A Urbina; J Gascón
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

Review 5.  Chagas Disease in the United States: a Public Health Approach.

Authors:  Caryn Bern; Louisa A Messenger; Jeffrey D Whitman; James H Maguire
Journal:  Clin Microbiol Rev       Date:  2019-11-27       Impact factor: 26.132

6.  Success of benznidazole chemotherapy in chronic Trypanosoma cruzi-infected patients with a sustained negative PCR result.

Authors:  L Murcia; B Carrilero; F Ferrer; M Roig; F Franco; M Segovia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-04       Impact factor: 3.267

Review 7.  Autoimmune pathogenesis of Chagas heart disease: looking back, looking ahead.

Authors:  Kevin M Bonney; David M Engman
Journal:  Am J Pathol       Date:  2015-04-07       Impact factor: 4.307

8.  The long way to defeating Chagas cardiomyopathy.

Authors:  Mario Petretta; Alberto Cuocolo
Journal:  J Nucl Cardiol       Date:  2018-02-21       Impact factor: 5.952

9.  Chagas Disease: A Solvable Problem, Ignored.

Authors:  Rick L Tarleton
Journal:  Trends Mol Med       Date:  2016-08-11       Impact factor: 11.951

10.  New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: a Pilot Short-Term Follow-Up Study with Adult Patients.

Authors:  María Gabriela Álvarez; Yolanda Hernández; Graciela Bertocchi; Marisa Fernández; Bruno Lococo; Juan Carlos Ramírez; Carolina Cura; Constanza Lopez Albizu; Alejandro Schijman; Marcelo Abril; Sergio Sosa-Estani; Rodolfo Viotti
Journal:  Antimicrob Agents Chemother       Date:  2015-11-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.